EUVIMEDEUVIMED entdecken
Crossref

Optimized Lipid Nanoparticles for Co‐Delivery of mRNA and siRNA Therapeutics in Refractory Liver Cancer

Yuqin Liao, Xiaodong Zeng, Xinwei Zhang, Yukun Hu, Yicheng Zhao, Qiusi Luo, Chunlin Ren, Haibing Zhou, Xuechuan Hong, Yuling Xiao iD

Advanced Materials · 2026-02 · 38 (11)

DOI: 10.1002/adma.202519473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 09.01.2026. Verfasst von Yuqin Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Nanoparticles, Liver Neoplasms, Lipids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: NSFC Key International (Regional) Joint Research Program, National Key R&D Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) exhibits poor prognosis and rapid resistance to sorafenib, particularly involving p53 loss and Nrf2 hyperactivation. Here, we employ machine learning (ML)‐assisted structure–activity relationship (SAR) analysis to guide the engineering of a library of 120 degradable ionizable lipids, enabling the rational design of fluorinated aromatic lipid nanoparticles (LNPs) optimized for combinatorial RNA delivery. ML‐based feature‐importance analysis prioritizes –CF 3 aromatic tails, and molecular dynamics simulations confirm that these tails enhance RNA binding and nanoparticle stability. The resulting A 2 T 5 ‐s LNPs, functionalized with lactobionic acid for selective HCC targeting, enable efficient co‐delivery of p53 mRNA and Nrf2 siRNA. This strategy restores ferroptosis and induces apoptosis in sorafenib‐resistant HCC by suppressing SLC7A11, leading to marked tumor inhibition. Our study demonstrates an ML‐assisted LNP optimization strategy, advancing precision RNA therapeutics to overcome resistance in refractory liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingNanoparticlesLiver NeoplasmsLipidsRNA, MessengerHumansSorafenibCell Line, TumorAnimalsCarcinoma, HepatocellularMachine LearningDrug Resistance, NeoplasmMolecular Dynamics SimulationStructure-Activity RelationshipFerroptosisLiposomes

Stichwörter der Autor:innen

co‐deliveryferroptosishepatocellular carcinomamachine learningsorafenib‐resistant

Substanzen

RNA, Small InterferingLipidsRNA, MessengerSorafenibLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Radiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.
  • State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute For Drug Discovery, Yantai, China.
  • School of Pharmacy, Shandong Second Medical University, Weifang, China.
  • Shenzhen Institute of Wuhan University, Shenzhen, China.
  • School of Pharmaceutical Sciences, Fudan University & National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China.

ORCID-Profile: Yuling Xiao

Förderung

  • NSFC Key International (Regional) Joint Research Program
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Research Grant
  • Guangdong Basic and Applied Basic Research Foundation
  • Tibet Autonomous Region Science and Technology Plan Project Key Project
  • Science and Technology Planning Project of Lhasa
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Liao, Y., Zeng, X., Zhang, X., Hu, Y., Zhao, Y., Luo, Q., Ren, C., Zhou, H., Hong, X., & Xiao, Y. (2026). Optimized Lipid Nanoparticles for Co‐Delivery of mRNA and siRNA Therapeutics in Refractory Liver Cancer. Advanced Materials, 38(11). https://doi.org/10.1002/adma.202519473

Vancouver

Liao Y, Zeng X, Zhang X, Hu Y, Zhao Y, Luo Q, et al. Optimized Lipid Nanoparticles for Co‐Delivery of mRNA and siRNA Therapeutics in Refractory Liver Cancer. Advanced Materials. 2026;38(11). doi:10.1002/adma.202519473

BibTeX
@article{Liao2026,
  author = {Liao, Yuqin and Zeng, Xiaodong and Zhang, Xinwei and Hu, Yukun and Zhao, Yicheng and Luo, Qiusi and Ren, Chunlin and Zhou, Haibing and Hong, Xuechuan and Xiao, Yuling},
  title = {Optimized Lipid Nanoparticles for Co‐Delivery of mRNA and siRNA Therapeutics in Refractory Liver Cancer},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {11},
  doi = {10.1002/adma.202519473}
}
Kostenlos starten →